Patents Examined by Robert T. Crow
  • Patent number: 10993933
    Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 4, 2021
    Assignee: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Margaretha Olthoff
  • Patent number: 10993459
    Abstract: A method for unlocking bioactive proteins that can then be used to activate natural remedies. The method includes starting with Silica salt and water mixture. Then a base of whey protein concentrate is added to the mixture. The pH of the whey protein mixture is raised using a base. The pH is held at a level above 11 for at least two hours. After at least two hours an acid is then added to the mixture to bring the pH of the mixture below 3 pH. This will stop the activation process. After the unattached proteins are removed the protein mixture is then brought back to a normal pH level, around 4 pH.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 4, 2021
    Inventor: Ralph Yoder
  • Patent number: 10974244
    Abstract: The present disclosure relates to devices and methods for the detection and/or sorting of nucleic acids. Further disclosed are methods for device fabrication.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 13, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA
    Inventor: Qiang Huang
  • Patent number: 10959967
    Abstract: The present invention is directed to effervescent compositions comprising a basic amino acid.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: March 30, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Rajnish Kohli, Richard Scott Robinson, Ralph Peter Santarpia, III, James R. Brown, Richard J. Sullivan, Michael Prencipe
  • Patent number: 10959427
    Abstract: The present disclosure provides a ladybug attractant, the ladybug being a natural enemy of an aphid, the ladybug attractant including a ladybug sex pheromone, a synomone and a kairomone; wherein the synomone is an aphid-induced plant volatile; the kairomone is composed of an aphid alarm pheromone, an aphid body surface extract and an aphid honeydew volatile. The ladybug attractant shows good attracting effect, good repeatability, high stability, and a broad spectrum of beneficial ladybugs such as Coccinella septempunctata, Harmonia axyridis, and Propylaea japonica in laboratory and field experiments.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: March 30, 2021
    Assignee: Zhejiang University
    Inventors: Jinhao Zhao, Zhongshan Li, Biao Wang, Zhongyan Wang, Jingli Cheng, Yongjun Du
  • Patent number: 10955380
    Abstract: A nanoscale protein-sensing platform with a non-equilibrium on-off switch that employs dielectrophoretic and hydrodynamic shear forces to overcome these thermodynamic limitations with irreversible kinetics. The detection sensitivity is achieved with complete association of the antibody-antigen-antibody (Ab-Ag-Ab) complex by precisely and rapidly assembling carbon nanotubes (CNT) across two parallel electrodes via sequential DC electrophoresis and dielectrophoresis (DEP), and with single-CNT electron tunneling conductance. The high selectivity is achieved with a critical hydrodynamic shear rate between the activated dissociation shear rates of target and non-target linkers of the aligned CNTs.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 23, 2021
    Assignee: University of Notre Dame du Lac
    Inventors: Hsueh-Chia Chang, Diya Li, Satyajyoti Senapati
  • Patent number: 10946041
    Abstract: Methods, compounds, and solutions for neurotransmitter restoration in a mammalian brain. The compound comprises calcium carbonate, pyridoxine hydrochloric acid, magnesium citrate, zinc amino acid chelate, chromium amino acid chelate, and a mixture comprising L-Tryptophan, L-Glutamine, L-Tyrosine, DL-Phenylalanine, and rhodiola. A visual indicator may be included to provide a easily discernable indication of the efficacy of a mixed solution.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: March 16, 2021
    Inventor: Patrece Frisbee
  • Patent number: 10947528
    Abstract: The present invention relates to a microfluidic device for extracting and isolating DNA from cells. The device includes a support having an inlet port for receiving a sample containing a cell, an outlet port for dispensing DNA isolated from the cell, and a microfluidic channel disposed within the support and extending from the inlet port to the outlet port. The microfluidic channel includes a micropillar array, an inflow channel disposed between the inlet port and the micropillar array, and an outflow channel disposed between the micropillar array and the outlet port. The micropillar array includes micropillars spatially configured to entrap, by size exclusion, the cell, to immobilize DNA released from the cell, and to maintain the immobilized DNA in elongated or non-elongated form when hydrodynamic force is applied to the microfluidic channel. Systems and methods of making and using the device are also provided herein.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 16, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Harold G. Craighead, Juraj Topolancik, Harvey Tian, Christopher Wallin
  • Patent number: 10940157
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 9, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10925882
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 23, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10918649
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 16, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10915023
    Abstract: A crosslinked self-assembled monolayer (SAM), comprising surface groups containing a nitrogen-heterocycle, was formed on an oxygen plasma-treated silicon oxide or hafnium oxide top surface of a substrate. The SAM is covalently bound to the underlying oxide layer. The SAM was patterned by direct write methods using ultraviolet (UV) light of wavelength 193 nm or an electron beam, forming a line-space pattern comprising non-exposed SAM features. The non-exposed SAM features non-covalently bound DNA-wrapped carbon nanotubes (DNA-CNT) deposited from aqueous solution with a selective placement efficiency of about 90%. Good alignment of carbon nanotubes to the long axis of the SAM features was also observed. The resulting patterned biopolymer features were used to prepare a CNT based field effect transistor.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 9, 2021
    Assignee: International Business Machines Corporation
    Inventors: Shu-Jen Han, Brian Lin, Hareem T. Maune, Charles T. Rettner, Linda K. Sundberg, Leslie E. Thompson, Hoa D. Truong
  • Patent number: 10898513
    Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: January 26, 2021
    Assignee: Hope Medical Enterprises, Inc.
    Inventors: Craig Sherman, Anthony James Lepine, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
  • Patent number: 10889857
    Abstract: Apparatus and methods relating to DNA sequencing are provided. In one embodiment, a DNA sequencing device includes a nanochannel having a width that is approximately 0.3 nm to approximately 20 nm. A pair of electrodes having portions exposed to the nanochannel may form a tunneling current electrode (TCE) with an electrode gap of approximately 0.1 nm to approximately 2 nm, and more particularly about 0.3 nm to about 1 nm. In one embodiment, at least one of the pair of electrodes is formed as a suspended electrode. An actuator may be associated with the suspended electrode to displace it relative to the other electrode. In various embodiments, the nanochannel and/or the electrodes may be formed using thermal reflow processes to reduce the size of such features.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: January 12, 2021
    Assignee: SEAGATE TECHNOLOGY LLC
    Inventors: Xiaomin Yang, ShuaiGang Xiao, David S. Kuo, Koichi Wago, Thomas Young Chang
  • Patent number: 10874691
    Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 29, 2020
    Assignee: Hope Medical Enterprises, Inc.
    Inventors: Craig Sherman, Anthony James Lepine, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
  • Patent number: 10876150
    Abstract: Gold nanorattle probes are provided that are highly tunable, physiologically stable, and ultra-bright Raman probes for in vitro and in vivo surface-enhanced Raman scattering (SERS) applications. The nanorattles contain an essentially uniform gap between core and shell that is tunable and can range from 2 nm to 10 nm in width. This provides numerous advantages including allowing for increased loading with a variety of dye molecules that exhibit SERS in various spectral regions, including the “tissue optical window” for in vivo studies. In addition, the nanorattle probes provide an internal label when used in diagnostic methods to detect nucleic acids, proteins and other biotargets. The nanorattles have an essentially spherical gold metal nanoparticle core, a porous material of silver metal of an essentially uniform width surrounding the nanoparticle core that is loaded with one or more SERS reporter molecules, and an outer gold metal shell encapsulating the porous material.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: December 29, 2020
    Assignee: Duke University
    Inventors: Tuan Vo-Dinh, Naveen Gandra, Hoan T. Ngo
  • Patent number: 10866230
    Abstract: Provided herein are compositions, compounds, processes, and methods of use of 3D porous coating(s) on or near a nanopore(s) for analysis or detection of charged polymers such as nucleic acids, proteins, protein-nucleic acid complexes, small molecule-biological complexes, polymer-biological complexes, and/or polyelectrolytes.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: December 15, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Mark Grinstaff, Amit Meller, Joseph Hersey, Allison Squires
  • Patent number: 10837954
    Abstract: Disclosed herein are methods and compositions for detection of target small molecules in a mixed sample by performing a competition assay between the target and a surrogate and subsequently detecting the complex types in a nanopore device.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 17, 2020
    Assignee: Ontera Inc.
    Inventor: Trevor J. Morin
  • Patent number: 10823721
    Abstract: In some aspects the invention is directed to methods of analyzing a polynucleotide which include steps of directing to a nanopore an excitation beam having a predetermined polarization state; translocating a polynucleotide through the nanopore, wherein nucleotides of the polynucleotide are labeled with fluorescent labels having absorption dipoles and wherein the nanopore spatially orients the fluorescent labels so that during translocation the adsorption dipoles are substantially unresponsive to the excitation beam; detecting changes in fluorescent signals generated by the fluorescent labels as nucleotides with fluorescent labels exit the nanopore and absorption dipoles thereof become responsive to excitation by the excitation beam with the predetermined polarization state; and identifying nucleotides exiting the nanopore from the changes in fluorescent signals.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: November 3, 2020
    Assignee: Quantapore, Inc.
    Inventor: Brett N. Anderson
  • Patent number: 10792246
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 6, 2020
    Assignees: BIOXCEL THERAPEUTICS, INC., ARX, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart